Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vascular endothelial growth factor-2 gene therapy - Corautus Genetics

Drug Profile

Vascular endothelial growth factor-2 gene therapy - Corautus Genetics

Alternative Names: VEGF-2 gene therapy - Corautus Genetics

Latest Information Update: 11 Jun 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Human Genome Sciences
  • Developer Boston Scientific Corporation
  • Class Cytokine genes; Gene therapies; Growth factors
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Angina pectoris; Coronary artery restenosis; Diabetic neuropathies; Ischaemic heart disorders; Vascular disorders

Most Recent Events

  • 06 Jun 2007 Corautus Genetics has been acquired and merged into VIA Pharmaceuticals
  • 03 Nov 2006 Suspended - Phase-I for Diabetic neuropathies in USA (Parenteral)
  • 03 Nov 2006 Suspended - Phase-II for Angina pectoris in USA (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top